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Abstract
Background and Objective IPX066 is a multiparticulate
extended-release formulation of carbidopa–levodopa, de-
signed to produce prolonged therapeutic levodopa plasma
concentrations. This 9-month open-label extension study
assessed its long-term safety and clinical utility in early and
advanced Parkinson’s disease (PD).
Methods Participants were enrolled from two phase III
IPX066 studies and one open-label phase II study. Early
PD patients were titrated to an appropriate dosing regimen
while advanced patients started with regimens established
in the antecedent studies. Adjustment was allowed
throughout the extension. Clinical utility measures in-
cluded the Unified Parkinson’s Disease Rating Scale
(UPDRS) and Patient Global Impression (PGI) ratings.
Results Among 268 early PD patients, 53.4 % reported
adverse events (AEs) and 1.1 % (three patients)
discontinued due to AEs; the most frequent AEs were
nausea (5.6 %) and insomnia (5.6 %). Among 349
advanced patients, 60.2 % reported AEs and 3.7 % (13
patients) discontinued due to AEs; the most frequent AEs
were dyskinesia (6.9 %) and fall (6.6 %). At month 9 (or
early termination), 78.3 % of early patients were taking
IPX066 three times daily (median: 720 mg/day) and
87.7 % of advanced patients were taking IPX066 three or
four times daily (median: 1450 mg/day). Adjusting for
70 % bioavailability relative to immediate-release (IR)
carbidopa–levodopa, the median dosages correspond to
*500 and *1015 mg/day of IR levodopa in early and
advanced PD, respectively. Based on the plasma profiles
previously observed in PD patients, the IPX066 regimens
in the extension can be estimated to provide a levodopa
Cmax (maximum plasma drug concentration) similar to or
lower than that provided by IR regimens during the an-
tecedent trials. UPDRS and PGI findings showed sustained
treatment effects throughout the extension.
Conclusion During 9 months of extended use, IPX066
exhibited a safety/tolerability profile consistent with
dopaminergic PD therapy.
Trial registration: ClinicalTrials.gov NCT01096186.
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Key Points
Throughout 9 months of extended, open-label
treatment, IPX066, an investigational formulation of
carbidopa–levodopa, showed acceptable long-term
safety and tolerability in early and advanced
Parkinson’s disease (PD).
In early PD, most patients (*80 %) took IPX066
three times per day. Corrected for relative
bioavailability, the dosages resembled those reported
for immediate-release (IR) levodopa.
In advanced PD, most patients (*90 %) took
IPX066 three or four times per day. Corrected for
relative bioavailability, the dosages were higher than
those reported for IR levodopa, but this increase may
be required to prolong therapeutic concentrations.
1 Introduction
For treatment of Parkinson’s disease (PD), levodopa is the
most effective oral pharmacotherapy developed to date [1,
2], and is typically administered in combination with a
dopa-decarboxylase inhibitor such as carbidopa. As PD
progresses, however, long-term use of oral levodopa is
often associated with motor fluctuations, including ‘wear-
ing-off’ between doses, and dyskinesias (involuntary
movements) that often occur at times of peak levodopa
plasma concentrations and maximal levodopa benefit [3,
4]. Eventually, patients may experience distressing periods
of refractory, sometimes unpredictable, parkinsonism [5],
with a large detrimental impact on their quality of life [6,
7]. Neurophysiological research suggests that the compli-
cations may be an outcome of long-term non-physiological
pulsatile fluctuations in levodopa concentrations associated
with dosing of conventional oral levodopa products [8].
Indeed, in clinical studies, continuous levodopa infusion
has yielded significant reductions of ‘off’ time and
dyskinesia [9–11]. The development of a levodopa for-
mulation capable of delivering more stable plasma con-
centrations is therefore a major need for PD management.
Although a controlled-release formulation is available [12],
patients transferred to it from the immediate-release (IR)
levodopa formulation have not consistently experienced
significant ‘off’ time reduction [13–17] or a predictable
response [18–21].
IPX066 (Impax Laboratories, Inc., Hayward, CA, USA)
is an investigational multiparticulate, extended-release
(ER) formulation of carbidopa and levodopa in a 1:4 ratio.
It was designed to rapidly achieve therapeutic plasma
levodopa concentrations and maintain them for a prolonged
duration to allow a dosing interval of approximately 6 h in
both early and advanced disease [22]. In a phase II cross-
over study [23] comparing IPX066 pharmacokinetics with
those of IR carbidopa–levodopa (CD-LD) in advanced PD
patients with motor fluctuations, the IPX066 initial ab-
sorption rate was rapid, similar to that of IR CD-LD. In
addition, IPX066 maintained levodopa plasma concentra-
tions above 50 % of the maximum plasma drug concen-
tration (Cmax) for a longer duration than IR CD-LD (4 vs.
1.4 h). Compared with IR CD-LD, IPX066 also reduced
the levodopa Cmax/Cmin (minimum plasma drug concen-
tration) ratio (12.0 ± 18.5 vs. 82.2 ± 67.5) and fluctuation
index (1.5 ± 0.4 vs. 3.2 ± 1.3) at steady state. The
bioavailability of IPX066 was determined to be ap-
proximately 70 % in terms of levodopa area under the
plasma concentration–time curve (AUC) and 30 % in
terms of levodopa Cmax compared with IR CD-LD in ad-
vanced PD patients [23]. Phase III clinical trials have re-
ported the efficacy and safety of IPX066 during 30 weeks
of treatment in early PD [24] and 19 weeks of treatment
(including 6 weeks of IPX066 dose conversion) in ad-
vanced PD [25].
Here we present safety results, clinical utility findings,
and dosing regimens for IPX066 during its long-term use in
early and advanced PD patients.
2 Methods
2.1 Study Participants
All patients had completed either of two controlled IPX066
phase III clinical trials [24, 25] or a phase II crossover trial
[23] and continued to have a diagnosis of PD eligible for
levodopa therapy. One of the phase III trials, APEX-PD
[24], was a 30-week randomized, double-blind, double-
dummy, parallel-arm study of three fixed-dose IPX066
regimens vs. placebo in 381 early PD patients who were
naı̈ve to levodopa (not exposed to levodopa for[30 days,
and not within 4 weeks of enrollment) and were not being
treated with dopamine agonists. IPX066 or matching
placebo was titrated to 145, 245, or 390 mg three times
daily. The IPX066 regimens were estimated to produce
levodopa AUC values similar to those for IR CD-LD
regimens of 300, 500, and 800 mg/day and Cmax values
similar to those for IR CD-LD doses of 45, 75, and 120 mg,
respectively. The other phase III trial, ADVANCE-PD
[25], was a randomized, double-blind, double-dummy,
parallel-arm study of IPX066 vs. IR CD-LD in 393 ad-
vanced PD patients with at least 2.5 h/day of ‘off’ time.
During a 3-week open-label period, each patient’s IR
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CD-LD regimen was adjusted. Open-label conversion to
IPX066 was then performed during a 6-week period, based
on the adjusted IR CD-LD regimen. Patients were then
randomized to IPX066 or IR CD-LD for a 13-week
maintenance period. Advanced PD patients who had
completed an open-label, two-period (8 days per period)
crossover phase II study of IPX066 vs. IR CD-LD [23]
were also eligible for this extension trial.
2.2 Study Design
For patients who had completed their previous study within
4 weeks before enrolling in this trial, the termination visit
in each patient’s previous study served as this trial’s first
visit (extension baseline). However, patients who had
completed their previous study more than 4 weeks before
this extension were required to undergo the first-visit pro-
cedures to re-establish baseline measures. For all patients
who were enrolled from the phase II study, this gap ex-
ceeded 1 year, necessitating a baseline visit.
During the extension, all four strengths of IPX066
capsules (carbidopa/levodopa 23.5/95, 36.25/145, 48.75/
195, or 61.25/245 mg) were available for treating patients.
Individualized dosing regimens could be achieved by
combining different capsules. Because the blind in the
early PD study had not yet been broken, IPX066 was up-
titrated as if all early PD patients were levodopa-naı̈ve. The
recommended starting dosage was one 95 mg capsule three
times daily for approximately 3 days, with optional up-
titration every 3 days to one 145 mg capsule three times
daily, two 95 mg capsules three times daily, and then two
145 mg capsules three times daily. In advanced PD, the
recommended starting dosages were the same as those
established during the open-label dose conversion period in
the antecedent study. For all patients, the recommended
dosing interval was approximately every 6 h during waking
hours (three doses per day; e.g., at 6 a.m., noon, and
6 p.m.). Patients could also take a bedtime dose (four times
daily dosing) but were not to take more than five doses per
day. The between-dose interval could vary but had to be
C4 h. Regimen adjustment was allowed throughout the
extension at the investigators’ discretion.
Nonselective monoamine oxidase (MAO) inhibitors
were prohibited; rasagiline was allowed at therapeutic dose
ranges [26]. The study was registered with ClinicalTri-
als.gov (identifier: NCT01096186) [27].
2.3 Assessments
At months 1, 5, and 9 (or early termination), IPX066
dosing and safety were assessed, the latter from data in-
cluding adverse events (AEs) and vital signs. At months 1
and 9 (or early termination), clinical laboratory tests and
12-lead electrocardiograms were also performed. Clinical
utility was measured using the Unified Parkinson’s Disease
Rating Scale (UPDRS) Parts I–IV (assessed during the
patient’s ‘on’ state by a study investigator or appropriately
trained site personnel), Patient Global Impression (PGI)
scale, EuroQol 5-Dimension (EQ-5D) health-related qual-
ity of life scale, 39-item Parkinson’s Disease Questionnaire
(PDQ-39), and 36-item Short-Form (SF-36) health survey
questionnaire. The UPDRS, PGI, and PDQ-39 were
assessed at months 1, 5, and 9 (or early termination). EQ-
5D and SF-36 were assessed at months 5 and 9.
2.4 Statistical Methods
The extension’s safety data were summarized descriptive-
ly, with separate summaries for the early and advanced PD
groups, each of which included all patients who received
open-label IPX066. UPDRS scores for Part II (activities of
daily living) plus Part III (motor examination) are pre-
sented for five timepoints: baseline and end of study in the
preceding trial, and months 1, 5, and 9 of the extension.
PGI results are presented for extension months 1, 5, and 9,
with categories collapsed to three ratings: dissatis-
fied (‘‘somewhat,’’ ‘‘very,’’ or ‘‘very much’’); satisfied
(‘‘somewhat,’’ ‘‘very,’’ or ‘‘very much’’); and neither sat-
isfied nor dissatisfied.
To evaluate average ‘off’ time, a post hoc descriptive
analysis of scores on UPDRS Part IV, Question 39 (‘‘What
proportion of the waking day is the patient ‘off’ on aver-
age?’’) was completed for end-of-study data from the
preceding trial and for extension month 9. Question 39 is
scored 0 (none), 1 (1–25 %), 2 (26–50 %), 3 (51–75 %), or
4 (76–100 %).
3 Results
3.1 Patient Flow
At 80 sites in North America and Europe, a total of 617
patients were enrolled in the extension, beginning in March
2010. Of 300 eligible patients with early PD (all from
APEX-PD), 268 (89.3 %) enrolled. Among them, 254 pa-
tients (94.8 %) completed the extension. Of 395 eligible
patients with advanced PD, 349 (88.4 %) enrolled (336 from
ADVANCE-PD and 13 from the phase II study). Among
them, 313 patients (89.7 %) completed the extension.
During the extension, 22 patients (3.6 %) withdrew
consent, 16 (2.6 %) discontinued due to AEs, four (0.6 %)
discontinued due to lack of efficacy, and four (0.6 %) died
(Fig. 1). No early PD patients and one advanced PD patient
discontinued due to non-compliance with study drug. In-
cluding the length of treatment in the antecedent trials,
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early PD patients were treated with IPX066 for a total of
39–69 weeks, and advanced PD patients were treated with
IPX066 for a total of 40–58 weeks. The final patient
completed the extension in October 2011.
3.2 Baseline Characteristics
Overall, extension patients had a mean age of 64.1 years
(range 41–89 years), were almost entirely white (Table 1),
and comprised more males than females. However, the
proportion of females was higher in early PD than in ad-
vanced PD (42 vs. 35 %). On average, the early PD group
was older at diagnosis than the advanced PD group (62.4
vs. 55.5 years).
3.3 IPX066 Regimens in Early Parkinson’s Disease
(PD)
At month 9 of the extension (or early termination), 83.3 % of
the patients with early PD (219 of 263) were taking
435–1170 mg/day of IPX066, corresponding to ap-
proximately 300–820 mg/day of IR levodopa after correction
for 70 % relative bioavailability. The median
(mean ± standard deviation [SD]) total dosage of IPX066
was 720 (727 ± 325) mg/day, corresponding to ap-
proximately 500 mg/day of IR levodopa. The dosages were
similar to the IPX066 dosages used in the antecedent early
PD study (435, 735, or 1170 mg/day). In addition, 78.3 % of
the patients (206 of 263) had maintained their three times
Fig. 1 Patient disposition. PD
Parkinson’s disease
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daily dosing. Another 9.9 % were taking IPX066 twice
daily, one patient was taking it once daily, 11.0 % were taking
it four times daily, and one patient was taking it five times
daily.
3.4 IPX066 Regimens in Advanced PD
At month 9 (or early termination), 84.5 % of the patients
from ADVANCE-PD (278 of 329) were taking 800–
2450 mg/day of IPX066, corresponding to approximately
560–1715 mg/day of IR levodopa. Another 4.9 % were
taking \800 mg/day, and 10.6 % were taking [2450
mg/day. The median (mean ± SD) IPX066 dosage was
1450 (1618 ± 726) mg/day, corresponding to appro-
ximately 1015 mg/day of IR levodopa. In ADVANCE-
PD, the median (mean ± SD) IPX066 dosage among
patients who enrolled in the extension had been
1330 (1568 ± 697) mg/day; hence, the median and
mean increases during the extension were less than
10 %.
Table 1 Patient characteristics Characteristic Patients with early PD (n = 268) Patients with advanced PD (n = 349)
Agea (years)
Mean (SD) 65.0 (8.9) 63.4 (9.4)
Median [range] 65.5 [43–86] 64.0 [41–89]
Sex [n (%)]
Male 156 (58.2) 227 (65.0)
Female 112 (41.8) 112 (35.0)
Race [n (%)]
White 267 (99.6) 341 (97.7)
Black/African American 1 (0.4) 2 (0.6)
Asian 0 3 (0.9)
Other 0 3 (0.9)
Body mass indexa (kg/m2)
Mean (SD) 27.6 (4.6)b 27.4 (5.2)
Median [range] 27.0 [15.5–50.2] 26.3 [16.6–64.8]
PD durationa, c (years)
Mean (SD) 2.7 (2.4) 7.9 (4.5)
Median [range] 2.0 [1–19] 7.0 [1–29]
Age at PD diagnosisa (years)
Mean (SD) 62.4 (9.3) 55.5 (10.2)
Median [range] 62.5 [40–85] 56.0 [30–82]
Hoehn and Yahr stagea [n (%)]
I 28 (10.4) 9 (2.6)
II 179 (66.8) 195 (55.9)
III 61 (22.8) 129 (37.0)
IV 0 16 (4.6)
V 0 0
Concomitant PD medicationsd [n (%)]
Dopamine agonists 6 (2.2) 177 (50.7)
MAO-B inhibitors 77 (28.7) 82 (23.5)
Amantadine 52 (19.4) 67 (19.2)
Anticholinergics 13 (4.9) 16 (4.6)
Othere 71 (26.5) 40 (11.5)
CD-LD carbidopa–levodopa, CR controlled-release, IR immediate-release, MAO monoamine oxidase, PD
Parkinson’s disease, SD standard deviation
a At entry in the patient’s antecedent study
b n = 266
c Time since diagnosis
d Prior to patient’s entry into the extension
e IR CD-LD, CR CD-LD, entacapone, or IR CD-LD plus entacapone
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At month 9, 45.2, 42.5, and 10.6 % of advanced PD
patients were taking IPX066 three, four, or five times daily,
respectively, and four patients (1.2 %) were taking it more
than five times daily. For most patients, the dosing fre-
quency established during the preceding study was main-
tained at month 9, with 79.7, 82.2, and 83.3 % of patients
who took IPX066 three or fewer, four, or five times daily in
the preceding study still doing so.
3.5 Other PD Drugs
At extension entry, approximately half of the patients with
advanced PD and almost no patients with early PD were
using dopamine agonists (see Table 1). Approximately
one-quarter of patients in each group were using MAO-B
inhibitors, approximately one-fifth were using amantadine,
and less than 5 % were using anticholinergics.
Approximately one-quarter of the early PD patients and
one-tenth of the advanced PD patients reported using
levodopa-containing products during the gap between their
antecedent study and the extension. During the extension,
small proportions of patients—6.0 % of the early PD
patients (16 of 268) and 6.9 % of the advanced PD patients
(24 of 349)—continued taking levodopa-containing
medications. In addition, 3.4 % of the early PD patients (nine
of 268) and 3.2 % of the advanced PD patients (11 of 349)
continued to use a catechol-O-methyltransferase inhibitor.
3.6 Adverse Events
Among the 617 patients who entered the extension, 353
(57.2 %) reported AEs (Table 2). Only fall (reported by 32
patients, or 5.2 %) was reported by more than 5.0 % of the
total extension population. Among the AEs reported by
more than 5.0 % of patients in the early or advanced PD
subgroups, insomnia and nausea were reported by a greater
percentage of patients with early PD, whereas fall and
dyskinesia were reported by a greater percentage of pa-
tients with advanced PD. In early PD, dyskinesia was re-
ported by five patients (1.9 %), all of whom had been
treated with IPX066 in the original trial. In advanced PD,
dyskinesia was reported by 24 patients (6.9 %).
Four patients (0.6 %) died during the extension. Their
causes of death were hemorrhagic stroke, hemorrhagic
Table 2 Reported adverse events that started during the extensiona
Incidence [n (%)] All patients (N = 617) Patients with early PD (n = 268) Patients with advanced PD (n = 349)
At least 1 AE 353 (57.2) 143 (53.4) 210 (60.2)
Fall 32 (5.2) 9 (3.4) 23 (6.6)
Dyskinesia 29 (4.7) 5 (1.9) 24 (6.9)
Nausea 25 (4.1) 15 (5.6) 10 (2.9)
Insomnia 24 (3.9) 15 (5.6) 9 (2.6)
Back pain 19 (3.1) 9 (3.4) 10 (2.9)
Headache 18 (2.9) 10 (3.7) 8 (2.3)
Dizziness 17 (2.8) 9 (3.4) 8 (2.3)
Arthralgia 16 (2.6) 5 (1.9) 11 (3.2)
Constipation 16 (2.6) 7 (2.6) 9 (2.6)
Hypertension 15 (2.4) 11 (4.1) 4 (1.1)
Pain in extremity 15 (2.4) 2 (0.7) 13 (3.7)
Urinary tract infection 15 (2.4) 4 (1.5) 11 (3.2)
Hallucination 14 (2.3) 2 (0.7) 12 (3.4)
Depression 12 (1.9) 4 (1.5) 8 (2.3)
Tremor 12 (1.9) 8 (3.0) 4 (1.1)
Dry mouth 11 (1.8) 4 (1.5) 7 (2.0)
Anxiety 10 (1.6) 3 (1.1) 7 (2.0)
Upper respiratory tract infection 9 (1.5) 6 (2.2) 3 (0.9)
Worsening PD 8 (1.3) 6 (2.2) 2 (0.6)
Muscle spasms 7 (1.1) 0 7 (2.0)
Respiratory tract infection 7 (1.1) 0 7 (2.0)
Weight decreased 7 (1.1) 0 7 (2.0)
AE adverse event, PD Parkinson’s disease
a The listing includes all Medical Dictionary for Regulatory Activities (MedDRA) Version 12.1 Preferred Terms with a reported incidence
C2.0 % in the early or the advanced PD group
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pancreatitis, prostate cancer, and unknown. None of the
deaths was considered by the investigators to be related to
IPX066.
Forty-three patients (7.0 %) reported serious AEs. Those
reported for more than one patient were femoral neck
fracture (n = 3) and fall, atrial fibrillation, gastritis, hy-
ponatremia, spinal column stenosis, and spinal os-
teoarthritis (n = 2 each).
Sixteen patients (2.6 %) reported AEs as the reason for
withdrawal from the extension. Those reported for more
than one patient were nausea, hallucinations, and dizziness
(n = 2 each).
3.7 Clinical Utility
In early and in advanced PD, UPDRS Parts II ? III scores
throughout the extension maintained the mean improve-
ment seen during the previous studies (Table 3). In early
PD, patients previously on placebo attained mean scores
similar to those achieved by patients treated with IPX066
in the antecedent APEX-PD study (24.9 vs. 24.0 at month
9). In advanced PD, patients previously randomized to IR
CD-LD in the antecedent ADVANCE-PD study attained
mean scores similar to those achieved by patients ran-
domized to IPX066 in that study (28.1 vs. 28.2 at month 9).
Mean PDQ-39 total scores at month 9 showed some de-
cline of the improvement attained in the antecedent studies
for patients previously randomized to IPX066 treatment
(see Table 3). However, the scores at month 9 were similar
across all patients whether or not they received IPX066 in
the preceding studies. SF-36 and EQ-5D findings suggested
little change from the preceding studies (data not shown).
On the PGI scale, the proportion of patients satisfied with
their IPX066 therapy was approximately 80 % at each
extension timepoint (see Table 3).
In a post hoc analysis of time in the ‘off’ state, the mean
(SD) score on UPDRS Part IV, Question 39 among early
PD patients was 0.1 (0.52) at the end of their antecedent
trial, with 92.5 % (248 of 268) scoring 0 (‘‘none’’), and 0.1
(0.32) at extension month 9, and 90.6 % (230 of 253)
scoring 0. Among patients with advanced PD, the mean at
the end of their antecedent trial was 1.3 (0.58), with 4.2 %
(14 of 336) scoring 0, and 1.0 (0.59) at extension month 9,
and 14.7 % (46 of 313) scoring 0.
4 Discussion
During 9 months of extended, open-label treatment,
IPX066 continued to exhibit acceptable safety and tol-
erability profiles in patients with early or advanced PD. In
early PD, the most frequently reported AEs, nausea and
insomnia, are commonly reported for dopaminergic drugs
[2, 28]. In advanced PD, the most frequently reported AEs,
dyskinesia and fall, are commonly associated with PD
therapies and/or PD progression [2, 28].
It is worth noting that in early PD, the incidence of
dyskinesia reported as an AE during the open-label ex-
tension remained low, at 1.9 %, a rate similar to that re-
ported in the antecedent APEX-PD study (2.9 %) [24]. The
consistent, low dyskinesia AE rates observed during
IPX066 studies [23–25] may have resulted from a pro-
longed duration of therapeutic levodopa plasma concen-
trations and reduced peak/trough fluctuations [23], both of
which have been shown to reduce the severity of
dyskinesia in PD patients [29, 30]. In advanced PD, the
reported incidence of dyskinesia during the open-label
extension (6.9 %) was similar to that reported during the
open-label dose-conversion phase of the antecedent
ADVANCE-PD study (6 %) [25].
This study also demonstrated that IPX066 regimens
generally remained stable for the duration of the extension.
In early PD, most patients (*80 %) continued to take
IPX066 three times daily, and dosages were in the range of
those used in the antecedent APEX-PD study [24]. The
median dosage was 720 mg/day, which corresponds to
approximately 500 mg/day of IR levodopa after correction
for 70 % relative bioavailability, a dosage similar to the IR
dosages reported in other early PD studies [4, 31–33]. The
sustained benefit seen in UPDRS II ? III score differs
from the less sustained benefit reported in the ELLDOPA
(Earlier vs. Later Levodopa Therapy in Parkinson Disease)
study of levodopa in early PD [4], perhaps reflecting dif-
ferences in levodopa plasma profiles.
In advanced PD, most patients (*90 %) took IPX066
three or four times per day. The mean and median dosages
differed only slightly (\10 %) from those in the antecedent
ADVANCE-PD study, suggesting that the antecedent
study’s allotment of 6 weeks for dose conversion from IR
CD-LD had been appropriate. The median dosage was
1450 mg/day, corresponding to approximately
1000 mg/day of IR levodopa, which is higher than the
median dosage of approximately 800 mg/day of IR CD-LD
in studies of IPX066 [23, 25] and entacapone [34] in ad-
vanced PD with motor fluctuations. The higher dosage is
required to sustain therapeutic plasma concentrations of
levodopa and minimize the peak/trough fluctuations char-
acteristic of standard IR formulations. Although the dosa-
ges were higher, the extension’s advanced PD patients
benefitted from IPX066 treatment, and dyskinesia, as a
reported AE, remained infrequent throughout long-term
IPX066 use.
Interpretations of this study’s findings may be limited by
the trial’s open-label design and by the absence of placebo
or active comparator groups. In addition, the antecedent
double-blind studies differed in their study populations and
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Table 3 Clinical utility findings (observed cases)
Group/outcome measure Timepoint
Baseline of
previous study
End of previous
study
Extension
month 1
Extension
month 5
Extension
month 9
Early PD
UPDRS Parts II 1 III scorea
All patients
n 268 268 261 258 254
Mean (SD) 36.7 (13.5) 24.7 (13.2) 24.3 (12.5) 23.9 (12.3) 24.2 (12.4)
Prior IPX066
n 207 207 201 200 196
Mean (SD) 37.4 (14.4) 22.5 (12.6) 24.0 (13.0) 23.6 (12.8) 24.0 (12.9)
Prior placebo
n 61 61 60 58 58
Mean (SD) 34.3 (9.1) 32.3 (12.4) 25.4 (10.8) 25.0 (10.4) 24.9 (10.4)
PGI rating
n NA NA 260 258 259
Satisfiedb [n (%)] NA NA 202 (77.7) 212 (82.2) 216 (83.4)
Neither satisfied nor dissatisfied [n (%)] NA NA 39 (15.0) 28 (10.9) 22 (8.5)
Dissatisfiedc [n (%)] NA NA 19 (7.3) 18 (7.0) 21 (8.1)
PDQ-39 total score
All patients
n 268 268 260 257 253
Mean (SD) 25.4 (17.2) 21.4 (17.0) 21.8 (17.6) 23.2 (18.4) 23.1 (17.8)
Prior IPX066
n 207 207 200 199 195
Mean (SD) 26.3 (17.9) 20.9 (17.0) 22.1 (18.0) 23.2 (18.9) 23.2 (18.3)
Prior placebo
n 61 61 60 58 58
Mean (SD) 22.5 (14.5) 23.1 (17.2) 21.1 (16.6) 23.4 (16.3) 23.1 (16.2)
Advanced PD
UPDRS Parts II 1 III scorea
All patients
n 336 336 340 323 313
Mean (SD) 32.4 (14.9)d 28.1 (14.1)d 27.0 (14.4) 26.5 (13.8) 28.2 (13.8)
Prior db IPX066
n 173 173 174 169 163
Mean (SD) 32.7 (14.3)d 26.3 (12.5)d 26.2 (13.1) 26.1 (12.8) 28.2 (12.2)
Prior db IR CD-LD
n 163 163 166 154 150
Mean (SD) 32.0 (15.4)d 29.9 (15.3)d 27.9 (15.6) 27.1 (14.8) 28.1 (15.3)
PGI rating
n NA NA 339 323 340
Satisfiedb [n (%)] NA NA 261 (77) 269 (83.3) 272 (80)
Neither satisfied nor dissatisfied [n (%)] NA NA 44 (13) 31 (9.6) 32 (9.4)
Dissatisfiedc [n (%)] NA NA 34 (10) 23 (7.1) 36 (10.6)
PDQ-39 total score
All patients
n 334 336 336 322 311
Mean (SD) 31.3 (16.5) 27.7 (15.9) 27.5 (15.9) 28.5 (15.9) 29.7 (16.0)
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in the duration of IPX066 treatment [24, 25]. Hence, pa-
tients who entered the extension had differing prior expo-
sures to IPX066. Further, the APEX-PD study of patients
with early PD had a fixed-dose design vs. placebo [24]
while the ADVANCE-PD study utilized individualized
dosing of IPX066 vs. an active control, IR CD-LD [25].
Nevertheless, the effects of IPX066 treatment seen in the
original trials were sustained with longer exposure to
IPX066 in this extension study.
5 Conclusions
Administration of IPX066 for 9 months in early and ad-
vanced PD populations appeared to be well-tolerated and
exhibited safety patterns consistent with the known effects
of commercially available CD-LD products in the PD
population. Based on UPDRS and PGI findings, the clinical
utility of IPX066 was maintained throughout the study’s
extended treatment period.
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